Pharmaceutics
Pulmonary Delivery of Inhalable Sustained Release Nanocomposites Microparticles Encapsulating Osimertinib for Non-Small Cell Lung Cancer Therapy.
Iman M Alfagih, Alanood Almurshedi, Basmah Aldosari, Bushra Alquadeib, Baraa Hajjar, Hafsa Elwali, Hadeel ALtukhaim, Eman Alzahrani, Sara Alhumaidan, Ghaida Alharbi
Published: 202610.3390/pharmaceutics18010134
Abstract
Background/Objective: Osimertinib (OSI) is a third-generation tyrosine kinase inhibitor approved for non-small cell lung cancer (NSCLC) therapy. OSI is administered orally; this route limits the amount of OSI reaching the tumor in the lungs and is as…
Preview only. Read the full abstract at the source